Blue light cystoscopy reduces bladder cancer recurrence risk by 38% compared to white light cystoscopy, as shown in the BRAVO study. The BRAVO study used real-world data from 626 veterans, confirming ...

OSLO, Norway, Oct. 16, 2020 /PRNewswire/ -- Photocure ASA (OSE:PHO) today announces a highlight from the BLADDR 2020 congress, a poster presentation on new findings from the Nordic Flexible BLC ...

FDG PET-CT imaging in assessing interim response to neoadjuvant cisplatin-based chemotherapy (NAC) in muscle invasive bladder cancer (MIBC): A prospective study. Real-world treatment and quality of ...

OSLO, Norway, May 18, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the presentation of two Photocure-supported abstracts at the American Urological Association ...

Effects of perioperative chemotherapy on prognosis in muscle invasive bladder cancer treated with radical cystectomy. This is an ASCO Meeting Abstract from the 2024 ASCO Genitourinary Cancers ...

Decades ago, blue lights helped shoppers scope out sales. Today they’re helping urologists scope out cells – specifically those of non-muscle-invasive bladder cancer. UW Medicine urologists with ...

Bladder cancer affects more than 86,000 people in the United States each year, according to the American Cancer Society, with the majority being over age 55. And while the disease can often be ...

OSLO, Norway, Aug. 14, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced that the U.S. Food and Drug Administration (FDA) has published a proposed order in the ...

Photocure ASA ((PHCUF)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights ...

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ Endoscopy-America, Inc., a leader in endoscopy and related technology solutions, announced its system for performing Blue Light Cystoscopy with Cysview® ...